Atrial Fibrillation, PersistentAF BPNCT06433336
Effect of Blood Pressure on Cardiovascular Outcomes and Recurrence After Catheter Ablation in Patients With Atrial Fibrillation
An observational study of Atrial Fibrillation, Persistent and Blood Pressure, run by Lanzhou University Second Hospital at 1 site in China.
Trial summary
Effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patients with atrial fibrillation Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Atrial Fibrillation, Persistent, Blood Pressure
- How many people
- 800 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2019to 21 May 2024
- How long will I take part?
- 1 Year
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Between February 2019 and December 2024, 800 consecutive patients who had been referred to lanzhou University second Hospital for treatment of AF and underwent successful ablation were assessed
Who may be able to join
- The inclusion criteria were age \>18 years and a diagnosis of AF by electrocardiogram during the preceding six months or on admission
Who cannot join
- No follow-up
Trial locations and contacts
1 site in 1 country.
About this study
Effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patients with atrial fibrillation
- Conditions
- Atrial Fibrillation, Persistent, Blood Pressure
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patien | Atrial Fibrillation Recurrence Pulmonary Vein Isolation |
What is being measured
The primary outcome is the main question the study is designed to answer.
cardiovascular events
death AMI stroke
Measured: 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2024
- Study start1 Jan 2019
- Primary completion21 May 2024
- Study completion21 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation, PersistentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Lanzhou University Second Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiaowei Zhang, Lanzhou University Second Hospital
- Investigators
- xiao wei xiaowei zhang, PHD, Principal investigator, Lanzhou University Second Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06433336
- Sponsor's protocol ID
- lanzhou university second hosp
- Other IDs
- lanzhou university
- Acronym
- AF BP
- Status last verified
- May 2024
- First submitted
- 22 May 2024
- Last updated
- 29 May 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No